Zometa zoledronic acid: Post-marketing study data

A post-marketing study in 144 patients showed that 4 mg IV Zometa every 21 days plus docetaxel/carboplatin chemotherapy significantly increased median survival in lung cancer patients with bone metastases vs. chemotherapy alone (578 vs. 384 days, p<0.001). Zometa plus chemotherapy also significantly increased median time to disease progression vs. chemotherapy alone (265 vs. 150 days, p<0.001). Zometa showed a significant positive correlation between the number of cycles of therapy and total survival and time to progression (p<0.01 for both). There was no significant difference in pain effect between the two groups. Skeletal-related events (SREs) occurred in 4.5% and 5.2% of patients, respectively. Data were published in the International Journal of Cancer. ...